Stimulate the vitality of innovative entities! The Zhangjiang competition for high-value patent operation in the Yangtze River Delta has been launched, enhancing the "gold content" of patents
High value patents are the core carrier of innovation and an important resource for promoting industrial innovation and development. On the afternoon of September 5th, 2023, the launching ceremony of the "Zhongzhi Road" Yangtze River Delta High Value Patent Operation Competition in Zhangjiang and the biopharmaceutical special roadshow were held at Zhangjiang Science City.
The competition aims to enhance the patent operation capabilities of enterprises, fully realize the value of idle patents, and promote innovative development of enterprises. The reporter learned that since its launch in the city in June, the competition has set its first stop in Pudong in Zhangjiang. In the future, it will also focus on artificial intelligence and other tracks, holding special events.
Promote the efficient transformation and application of intellectual property rights
The 2023 "Zhongzhi Road" Yangtze River Delta High Value Patent Operation Competition is jointly organized by the National Intellectual Property International Operation Platform, Shanghai Intellectual Property Trading Center Co., Ltd., Jiangsu International Intellectual Property Operation Trading Center Co., Ltd., Zhejiang Intellectual Property Trading Center Co., Ltd., and Anhui Provincial Property Rights Trading Center Co., Ltd.
The competition is divided into three stages: preliminary, semi-final, and final. Among them, the preliminary round will set up competition areas in Shanghai, Jiangsu, Zhejiang, and Anhui, and release the "Top 100 List of 2023 'Zhongzhi Road' Yangtze River Delta High Value Patent Operation Competition". The semi-finals will invite nearly a hundred experts from universities, research institutes, hospitals, service institutions, enterprises, investment institutions, banks and other fields to screen and evaluate the shortlisted projects, and select high-quality projects to enter the finals.
The 2022 Shanghai Science and Technology Innovation Center Construction Report shows that the number of high-value invention patents per 10000 population in Shanghai has reached 40.9, and the quality of intellectual property creation is steadily improving. At present, the phenomenon of some high-value patented technologies not being fully utilized due to idle or insufficient operational capabilities still objectively exists.
As an ongoing Asia Pacific intellectual property center city, Shanghai has many explorations in intellectual property construction. As early as April 2018, the national intellectual property international operation platform was approved by the China National Intellectual Property Administration, and the platform entity company was established and listed in November of that year. The platform was settled in Zhangjiang Science City.
"The original intention and purpose of the 2023 'Zhongzhi Road' Yangtze River Delta High Value Patent Operation Competition is to screen out many patents with high value and can be quickly launched, and introduce them into professional incubators and industrial parks with distinctive features. This is conducive to industrial clustering, promoting efficient transformation and application of intellectual property and technological achievement property transactions." said Pan Xi, Chairman of the National Intellectual Property International Operation Platform.
Transforming a company's "patents" into "dividends" and "intellectual property" into "assets"
This competition focuses on exploring a group of high-quality patents and scientific and technological innovation projects with high innovation level, strong market competitiveness, and obvious patent advantages, further stimulating the vitality of innovation entities and promoting high-quality creation of intellectual property in the Yangtze River Delta. It is reported that more than 160 projects have been selected from over 300, and four teams with high-value patents were selected for a biopharmaceutical roadshow on the same day.
![Stimulate the vitality of innovative entities! The Zhangjiang competition for high-value patent operation in the Yangtze River Delta has been launched, enhancing the "gold content" of patents](https://a5qu.com/upload/images/9e73ea344c61857ea446eafc92bd8a67.jpg)
Established in Zhangjiang in 2018, Fukang Pharmaceutical is a clinical stage new drug research and development enterprise based in China and facing the world, committed to developing innovative drugs in the field of cancer diseases. The company is guided by the unmet clinical drug needs in China and globally, and designs and develops original new drugs with the potential of "First in Class" or "Best in Class", providing innovative treatment plans for cancer patients.
This year, Fukang Pharmaceutical acquired the world's only clinical PI3K from Karus Therapeutics in the UK β/δ Dual high selectivity inhibitors are being promoted for global registered clinical trials.
"In the favorable intellectual property atmosphere of Pudong New Area, we have already obtained over 100 patents, and the dual high selectivity inhibitors brought about by this have high value. Once launched, the market size will exceed 100 million US dollars." Yang Xingzhi, Senior Director of the General Manager's Office of Fukang Pharmaceutical, said, "The company is in the financing stage and hopes to enhance industry awareness through the competition."
Patent cultivation is transitioning from a focus on quantity to a focus on quality. In Zhangjiang, experts from the Chinese Academy of Sciences Shanghai Institute of Medicine, the Biochip National Engineering Research Center, Shanghai Pudong Bioindustry Industry Association, Shanghai Pharmaceutical Group Co., Ltd., and Shanghai University Science and Technology Development Center served as judges.
"In the process of transforming domestic biomedical projects from clinical to new drug listing and going global, patent protection must be provided." Ye Yang, Secretary of the Party Committee and Deputy Director of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, said, "The high-value patent operation contest is a very good cross integration process to show new drug projects to investors through the link of patents, test the value of these projects from the market perspective, and enhance the popularity of the industry."
Text: Yang Zhenying
*Reprinted from official WeChat account released by Pudong